Dr. Tai-An Lin joined SpringWorks in 2023. He has more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification to early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. Previously, Tai-An was Senior Vice President of Translational Science and Discovery Biology of Black Diamond Therapeutics. Before Black Diamond, Tai-An was a Director of Immuno-Oncology Translational Innovation Platform and Experimental Medicine at Merck KGaA/EMD Serono leading translational biomarker research team and IO precision medicine efforts. Prior to EMD Serono, Tai-An had extensive experience in leading multidisciplinary drug discovery teams and biology groups at global pharmaceutical companies including Bristol-Myers Squibb, Roche, and Janssen Pharmaceuticals; key accomplishments included early discovery efforts for several kinase inhibitors including dasatinib, and leadership of BMS’s linrodostat and Roche’s RG7185 projects.